Home  /   Products  /   Eye and ear  /   Diphenhydramine, interferon alfa-2b (Interferon-Oftalmo) eye drops 100000 IU/ml + 1 mg/ml – [10 ml vial]

Diphenhydramine, interferon alfa-2b (Interferon-Oftalmo) eye drops 100000 IU/ml + 1 mg/ml – [10 ml vial]

$12.42

Combined antiviral agent (cytokine + h1-histamine receptor blocker) for topical use in ophthalmology

SKU: 61648 Category:

Description

Interferon-Oftalmo Pharmacodynamics
Interferon-Oftalmo is a combined medicine containing antiviral and immunomodulatory agent – recombinant human interferon alfa-2b and antihistamine – diphenhydramine.
Pharmacodynamics
Interferon alpha-2b human recombinant has a wide range of antiviral activity, immunomodulatory, antiproliferative actions.
Diphenhydramine is a blocker of H1-histamine receptors, has an anti-allergic effect, reduces conjunctival edema and itching.

Indications
– Adenoviral, hemorrhagic (enterovirus), herpetic conjunctivitis;
– Adenoviral, herpetic (vesicular, pitting, tree-like, kart-like) keratitis;
– Herpetic stromal keratitis with and without corneal eruption;
– Adenoviral and herpetic keratoconjunctivitis;
– Herpetic uveitis;
– Herpetic keratouveitis (with or without deformities);
– Dry eye syndrome;
– Prevention of graft disease and prevention of herpetic keratitis recurrence after keratoplasty;
– Prevention and treatment of complications after excimer laser refractive corneal surgery.

Contraindications
Individual intolerance to the components of the drug.
Usage during pregnancy and lactation
The drug can be used during pregnancy and breast feeding only by prescription of a physician if the expected effect of the drug exceeds the risk of developing complications in the fetus and the newborn.
Before using Interferon-Oftalmo, if you are pregnant or think that you may be pregnant, or if you plan to become pregnant, it is necessary to consult with your doctor.

Dosage and administration

  • Topically, into the conjunctival sac.
  • In case of virus-induced eye damage in adults and children at acute stages of disease the drug is instilled into conjunctival sac 1 to 2 drops up to 6 to 8 times daily. As inflammatory process subsides, the number of drops is decreased to 2-3 times a day until disappearance of symptoms.
  • In “dry eye” syndrome the drug is applied daily by putting drops in the affected eye once or twice a day for 25-30 days until disappearance of symptoms.
  • For prevention and treatment of complications after excimer laser refractive surgery of cornea the drug is applied daily by putting 1-2 drops in the eye twice a day from the day after surgery for 10 days.
  • For prophylaxis of graft disease and prevention of herpetic keratitis recurrence after keratoplasty the drug is applied daily by putting 1-2 drops in the operated eye 3-4 times a day during the first two weeks after surgery.
  • If after treatment no improvement or aggravation of symptoms or appearance of new symptoms occurs, consult a doctor. Use the drug only according to the indications, the method of application and in such doses as specified in the instructions.